This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Egalet Appoints Jeffrey M. Dayno, M.D. As Chief Medical Officer

WAYNE, Pa., July 28, 2014 (GLOBE NEWSWIRE) -- Egalet Corporation (Nasdaq:EGLT) ("Egalet") today announced the appointment of Jeffrey M. Dayno, M.D. as chief medical officer (CMO). Dr. Dayno will be responsible for leading Egalet's clinical development programs as well as overseeing the activities in regulatory affairs, pharmacovigilance and medical affairs. Dr. Dayno will begin July 31.

"We would like to welcome Jeff to our management team at this critical time as we move our lead abuse-deterrent product candidate, Egalet-001, through the final phase of development and plan to file an NDA in the fourth quarter," said Bob Radie, president and CEO. "Jeff's deep global pharmaceutical and medical affairs experience in the neurology and pain areas will be invaluable as we advance our product candidates, develop our medical affairs/education strategies and evolve our commercial organization. We also would like to thank Roland Gerritsen van der Hoop M.D., Ph.D., our acting CMO, for his guidance over the past few years as he transitions to become an advisor to Egalet."

Dr. Dayno spent ten years in clinical and academic medicine before moving into the pharmaceutical industry. He most recently served as vice president, global medical affairs, at ViroPharma, a pharmaceutical company which was bought by Shire in 2014, where he was a member of several senior R&D leadership teams. Prior to joining ViroPharma, Dr. Dayno held the position of chief medical officer for Labopharm, Inc., a Canadian biotechnology company, where he oversaw all of the R&D activities and gained valuable experience working in the area of abuse-deterrent opioid product development. Before Labopharm he was the vice president, medical services, at Cephalon where he directed Cephalon's Phase 3B/4 clinical development programs. Dr. Dayno started his career in pharma at Merck & Co., Inc. where he spent seven years in roles of increasing responsibility in the medical and scientific affairs division. In total he has 16 years of experience in pharmaceutical medicine during which time he oversaw and provided strategic guidance to clinical development programs, interacted with regulatory authorities around the world, built and led medical affairs departments and orchestrated the integration of these functions in support of commercial franchises. 

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs